Key facts
- It has raised $2.7M across 1 recorded rounds; the latest was Seed Round ($2.2M) in Nov 2024.
- Notable investors include Y Combinator, Alumni Ventures, 468 Capital, Multimodal Ventures, Ajira Ventures — 7 tracked in total.
- Exin Therapeutics has filed 1 Form D with the SEC, most recently Feb 2026 ($2.2M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Exin Therapeutics
Funding rounds
1 roundsAbout Exin Therapeutics
Developer of a genetic therapy platform intended to target neurological and neuropsychiatric disorders from a circuit-level perspective. The company improves the lives of patients by focusing on correcting excitatory and inhibitory signal imbalances in targeted brain circuits, enabling people with idiopathic cases to benefit from it.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 7
- Website
- exintherapeutics.com/
- Ownership
- Privately Held (backing)
Exin Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exin Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exin Therapeutics in its N-PORT filings yet. We sweep new filings monthly.